Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors - Wikidata - wikimedia - TriplyDB

Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors

Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors

http://www.wikidata.org/entity/Q28292264

about

The Human Kinome Targeted by FDA Approved Multi-Target Drugs and Combination Products: A Comparative Study from the Drug-Target Interaction Network Perspective Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer Epigenetic assays for chemical biology and drug discovery.ErbB expression, activation, and inhibition with lapatinib and tyrphostin (AG825) in human vestibular schwannomas.FOXO3a represses VEGF expression through FOXM1-dependent and -independent mechanisms in breast cancer.FoxM1 mediated resistance to gefitinib in non-small-cell lung cancer cells Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy The escalating role of epidermal growth factor receptor inhibitors in cancer management: clinical considerations for the health system pharmacist.Lapatinib for the treatment of breast cancer in the People's Republic of China.Clinical Experience with Lapatinib in Patients with ErbB2-Overexpressing Metastatic Breast Cancer Lapatinib - Member of a New Generation of ErbB-Targeting Drugs.Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine.FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer ErbB receptor-driven prolactinomas respond to targeted lapatinib treatment in female transgenic mice Tyrosine kinase inhibitors: Multi-targeted or single-targeted?Deciphering the role of forkhead transcription factors in cancer therapy An HPLC method for the determination of a novel anti-hypertension agent 6,7-dimethoxy-3-(4-(4-fluorobenzyloxy)-3-methoxyphenylmethyl)quinazolin-4(3H)-one in rat plasma: application to pharmacokinetic study.N⁴-(3-Bromophenyl)-7-(substituted benzyl) pyrrolo[2,3-d]pyrimidines as potent multiple receptor tyrosine kinase inhibitors: design, synthesis, and in vivo evaluation.The Akt signaling pathway: an emerging therapeutic target in malignant melanoma.Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition.Plant lectin can target receptors containing sialic acid, exemplified by podoplanin, to inhibit transformed cell growth and migration.Understanding drugs in breast cancer through drug sensitivity screening Development of a test that measures real-time HER2 signaling function in live breast cancer cell lines and primary cells.Induction of caspase-dependent extrinsic apoptosis by apigenin through inhibition of signal transducer and activator of transcription 3 (STAT3) signalling in HER2-overexpressing BT-474 breast cancer cells.Mechanisms of drug inhibition of signalling molecules.N2-Trimethylacetyl substituted and unsubstituted-N4-phenylsubstituted-6-(2-pyridin-2-ylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines: design, cellular receptor tyrosine kinase inhibitory activities and in vivo evaluation as antiangiogenic, antimet A review of lapatinib ditosylate in the treatment of refractory or advanced breast cancer.Design, synthesis and biological evaluation of substituted pyrrolo[2,3-d]pyrimidines as multiple receptor tyrosine kinase inhibitors and antiangiogenic agents Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3 Jumping higher: is it still possible? The ALTTO trial challenge.Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma Genomic and proteomic biomarkers for cancer: a multitude of opportunities.The Paradox of Oestradiol-Induced Breast Cancer Cell Growth and Apoptosis.Safety of triazole antifungal drugs in patients with cancer.Growth factors as active participants in carcinogenesis: a perspective.Radiosensitizing effect of lapatinib in human epidermal growth factor receptor 2-positive breast cancer cells.Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines.Boron-Based Drug Design.Mechanisms of tumor cell resistance to the current targeted-therapy agents.Antibody and lectin target podoplanin to inhibit oral squamous carcinoma cell migration and viability by distinct mechanisms.

P2860

Q28553277-62BC0871-6B66-4AA8-AFC4-9B79537911AE Q29618155-E99445E6-EEE0-4942-BF5D-22F7167E3C83 Q30358152-0D848D12-06E6-4677-9526-7525381232EC Q30457869-73B767D2-D51A-40A6-ACE9-51745A6E289D Q32884377-9955A630-3284-4F79-8075-EB81095E56DA Q33567379-263E2D25-FA18-4FF7-BD3B-35E70D16BA46 Q33828409-444927FA-6E99-49A4-B5C0-1996C0069D08 Q33865354-8178EECE-AF4B-4C94-9D76-09A475F09A88 Q34016491-24573234-5804-40F1-9F3B-BE1D485CB0D6 Q34095748-772B1118-6886-47BE-BC59-1B9D1CF317E0 Q34096228-1B0387E5-721D-4F54-8A2F-87005FE4D4B8 Q34235124-9739CD79-6CBD-42E9-BDFE-9A585F8185E3 Q34725700-80944868-5633-4036-83C0-53649896C20A Q34745279-1E778DD0-23E0-41C9-A20F-C24398015009 Q34983846-56881666-26C2-4408-91B0-FD7D4BDD8E37 Q35146638-E399F4D6-5ADA-4B4D-A69B-AB38CC382F36 Q35844860-1870AB40-CA08-4CE7-9624-EAB5C2BC7DE0 Q35848191-C742D86B-4DD8-4FFA-8AC8-2AFEC2DEF816 Q35911227-1BB95893-B32D-4AFF-BABF-789DBD2D709C Q36062158-ABACB39C-79E8-407F-81E3-A39596EEC664 Q36109632-8AE8A6DA-A80A-4B7E-90E6-965B6C9483C0 Q36234079-57DCDA97-57A7-41C9-AF33-0E27B367AF7F Q36311216-205AD063-96C2-4D26-BC4C-4E05A7F8C668 Q36450288-31CB2259-6EA6-4E9A-8B92-85CF814296C5 Q36488752-F7583983-5F93-4FB0-9919-51F54D9BFDE3 Q36614871-C6B2E71C-DBC9-48AF-8CAC-A548EFBCC098 Q36642955-549E1386-73DC-4C94-9812-DF92755CBC18 Q36775982-4918ABC3-1AA6-40BC-AC97-DE75BB1AA8BA Q36793441-36725B76-D5A5-4D08-9908-9B8C471847BE Q37338235-1EF7EB42-FB9B-48AC-B7B9-BF09C8AF42CD Q37351498-A8B5CB81-4FC2-4361-BED4-0E403E66EFA9 Q37363928-6C4396B0-8345-4413-986B-2139076BDA1D Q37376013-2925B498-0B90-4B7F-A608-722D9B9620A4 Q37662650-C19E76FD-9ED4-4064-833D-126B2163047C Q37676697-9DF83C2D-0588-4E37-9B2A-D123637F3F17 Q37694756-A0FC9AA8-5C39-4FF0-A603-57E8BD1589CA Q37873453-A0596889-3FAC-493A-8FA8-4DA9CB5D5DE6 Q38387948-5E8A7BB1-102E-438F-89A6-3C79ED8DFDFE Q38828353-E9B54E3A-E3AF-487D-BF9C-273D745F2F15 Q38892678-A450E7B4-19A3-4DCE-A2C8-6CB1ECEEDDB2

P2860

Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors

http://www.wikidata.org/entity/Q28292264

description

2006 nî lūn-bûn

@nan

2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

name

Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors

@ast

Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors

@en

Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors

@nl

type

label

Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors

@ast

Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors

@en

Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors

@nl

prefLabel

Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors

@ast

Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors

@en

Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors

@nl

P1433

Q28292264-D2D22C6A-4C29-4ACF-80FD-1F03BB3DD9FF

P1476

Q28292264-8C04FB3E-53F2-4FE7-93E0-BD317A718365

P2093

Q28292264-55B5A5D1-DEA2-48D5-BB62-6F3C43576D94

Q28292264-73343A62-3C2D-4172-8BA2-87DEC500D823

P2860

Q28292264-095BF7D8-96A0-4588-A381-CC5F6F192AD7

Q28292264-0C6C7FB9-241F-4D40-8248-552C43195DCB

Q28292264-1886C094-B599-4ACE-99B5-6DCA1417EC08

Q28292264-1BF5D780-80E9-4F67-9E2E-6777E1A2E89E

Q28292264-26725915-31C5-44FA-8F04-55B2E9B28A49

Q28292264-3B57755F-EE8C-40F7-B5F8-704C462777A1

Q28292264-3E71F402-ACE1-469C-8432-B8570D7496F8

Q28292264-44A40C65-3201-4A3F-9638-0034AABB5F8E

Q28292264-486A86A4-7E7B-4A53-9454-4799A7FCC48E

Q28292264-4D211264-D1BA-4CE9-93DD-92E8F2A20A8A

P304

Q28292264-41B56A3F-FDBC-4643-9A94-DD231B7AB1E5

P31

Q28292264-487814F0-38E2-404E-ABB6-ABF640F26340

P3181

Q28292264-7718055B-2E5D-4CC7-B660-EE8D3915EC60

P356

Q28292264-65298086-DF7B-4426-B2FA-CEB4F4EDE6AB

P407

Q28292264-52589518-7716-415D-B212-D27DE4038994

P433

Q28292264-CC540BE6-2F9C-4846-BC71-9651E8FFD5F6

P478

Q28292264-D04E67F5-1304-4EF0-8516-436BBFA714D0

P577

Q28292264-077DB74D-ACC7-49BF-BFBF-A4D054CF7998

P698

Q28292264-AA54D12C-E36D-4D8A-8730-AB3243580297

P3181

P356

P1433

Annals of Pharmacotherapy

P1476

Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors

@en

P2093

Christian R Dolder

http://www.w3.org/2001/XMLSchema#string

Michael H Nelson

http://www.w3.org/2001/XMLSchema#string

P2860

New targets for therapy in breast cancer: small molecule tyrosine kinase inhibitors

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells

Role of HER2/neu in tumor progression and therapy

The relationship between human epidermal growth-like factor receptor expression and cellular transformation in NIH3T3 cells

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

Epidermal growth factor receptors: critical mediators of multiple receptor pathways.

P304

261-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2614821

http://www.w3.org/2001/XMLSchema#string

P356

10.1345/APH.1G387

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

40

http://www.w3.org/2001/XMLSchema#string

P577

2006-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16418322

http://www.w3.org/2001/XMLSchema#string